Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Gastric Cancer | Research

The relationship between pepsinogen C and gastric carcinogenesis: a transgene and population study

Authors: Ying E., Qian Yu, Tao Sun, Hang Xue, Xue-rong Zhao, Hua-chuan Zheng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Pepsinogen C (PGC) is expressed in chief cells, fundic mucous neck cells, and pyloric gland cells of gastric epithelium and also in breast, prostate, lung, and seminal vesicles.

Methods

We explored the clinicopathological and prognostic significances of PGC mRNA using pathological and bioinformatics analyses. We generated PGC knockout and PGC-cre transgenic mice to observe the effects of PGC deletion and PTEN abrogation in PGC-positive cells on gastric carcinogenesis. Finally, we observed the effects of altered PGC expression on aggressive phenotypes by CCK8, Annexin V staining, wound healing and transwell assays and analyzed the partner proteins of PGC using co-IP (co-immunoprecipitation) and double fluorescence staining.

Results

PGC mRNA level was inversely correlated with the T and G stage and a short survival of gastric cancer (p < 0.05). PGC protein expression was negatively linked to lymph node metastasis, dedifferentiation, and low Her-2 expression of gastric cancer (p < 0.05). No difference in body weight or length was evident between wild-type (WT) and PGC knockout (KO) mice (p > 0.05), but PGC KO mice had a shorter survival than WT mice (p < 0.05). No gastric lesions were observed in the mucosa of the granular stomach in PGC KO mice, which displayed lower frequency and severity of gastric lesion than in WT mice after treated with MNU. Transgenic PGC-cre mice showed high cre expression and activity in the lung, stomach, kidney, and breast. Gastric cancer and triple-negative lobular breast adenocarcinoma were found in PGC-cre/PTENf/f mice with two previous pregnancies and breast feeding, but breast cancer was not seen in transgenic mice exposed to either estrogen or progesterone, or those with two previous pregnancies and no breast feeding. PGC suppressed proliferation, migration, invasion, and induced apoptosis, and interacted with CCNT1, CNDP2 and CTSB.

Conclusion

PGC downregulation was seen in gastric cancer, but PGC deletion resulted in resistance to chemically-induced gastric carcinogenesis. PGC expression suppressed the proliferation and invasion of gastric cancer cells possibly by interacting with CCNT1, CNDP2 and CTSB. Spontaneous triple-negative lobular adenocarcinoma and gastric cancer were seen in PGC-cre/PTENf/f mice, and the breast carcinogenesis was closely linked to pregnancy and breast feeding, but not to single exposure to estrogen or progesterone, or pregnancy. Limiting either pregnancy or breast feeding might help to prevent hereditary breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhao Z, Hou N, Sun Y, et al. Atp4b promoter directs the expression of cre recombinase in gastric parietal cells of transgenic mice. J Genet Genomics. 2010;37:647–52.PubMedCrossRef Zhao Z, Hou N, Sun Y, et al. Atp4b promoter directs the expression of cre recombinase in gastric parietal cells of transgenic mice. J Genet Genomics. 2010;37:647–52.PubMedCrossRef
2.
go back to reference Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007;133(2):659–72.PubMedCrossRef Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007;133(2):659–72.PubMedCrossRef
4.
go back to reference Oshima H, Matsunaga A, Fujimura T, et al. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterol. 2006;131:1086–95.CrossRef Oshima H, Matsunaga A, Fujimura T, et al. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterol. 2006;131:1086–95.CrossRef
5.
go back to reference Li XB, Yang G, Zhu L, et al. Gastric Lgr5 (+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice. Cell Res. 2016;26:838–49.PubMedPubMedCentralCrossRef Li XB, Yang G, Zhu L, et al. Gastric Lgr5 (+) stem cells are the cellular origin of invasive intestinal-type gastric cancer in mice. Cell Res. 2016;26:838–49.PubMedPubMedCentralCrossRef
6.
go back to reference Syder AJ, Karam SM, Mills JC, et al. A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci U S A. 2004;101:4471–6.PubMedPubMedCentralCrossRef Syder AJ, Karam SM, Mills JC, et al. A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci U S A. 2004;101:4471–6.PubMedPubMedCentralCrossRef
7.
go back to reference Shimada S, Mimata A, Sekine M, et al. Synergistic tumor suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 2012;61:344–53.PubMedCrossRef Shimada S, Mimata A, Sekine M, et al. Synergistic tumor suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut. 2012;61:344–53.PubMedCrossRef
8.
go back to reference Zhao GF, Zhao S, Liu JJ, et al. Cytokeratin 19 promoter directs the expression of Cre recombinase in various epithelia of transgenic mice. Oncotarget. 2017;8(11):18303–11.PubMedPubMedCentralCrossRef Zhao GF, Zhao S, Liu JJ, et al. Cytokeratin 19 promoter directs the expression of Cre recombinase in various epithelia of transgenic mice. Oncotarget. 2017;8(11):18303–11.PubMedPubMedCentralCrossRef
9.
go back to reference Wang S, Cao YF, Sun XY, Hong M, Fang ZZ, Luo HH, Sun H, Yang P. Plasma amino acids and residual hypertriglyceridemia in diabetic patients under statins: two independent cross-sectional hospital-based cohorts. Front Cardiovasc Med. 2021;8:605716.PubMedPubMedCentralCrossRef Wang S, Cao YF, Sun XY, Hong M, Fang ZZ, Luo HH, Sun H, Yang P. Plasma amino acids and residual hypertriglyceridemia in diabetic patients under statins: two independent cross-sectional hospital-based cohorts. Front Cardiovasc Med. 2021;8:605716.PubMedPubMedCentralCrossRef
10.
go back to reference Yada T, Ito K, Suzuki K, et al. Marked decrease in serum pepsinogen II levels resulting from endoscopic resection of a large duodenal tumor. Clin J Gastroenterol. 2014;7(6):484–9.PubMedPubMedCentralCrossRef Yada T, Ito K, Suzuki K, et al. Marked decrease in serum pepsinogen II levels resulting from endoscopic resection of a large duodenal tumor. Clin J Gastroenterol. 2014;7(6):484–9.PubMedPubMedCentralCrossRef
11.
go back to reference Antunes AA, Leite KR, Sousa-Canavez JM, et al. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. J Urol. 2009;181(2):594–600.PubMedCrossRef Antunes AA, Leite KR, Sousa-Canavez JM, et al. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis. J Urol. 2009;181(2):594–600.PubMedCrossRef
12.
go back to reference Quintela I, Vizoso F, Serra C, et al. Immunohistochemical study of pepsinogen C expression in cutaneous malignant melanoma: association with clinicopathological parameters. Int J Biol Markers. 2001;16(4):240–4.PubMedCrossRef Quintela I, Vizoso F, Serra C, et al. Immunohistochemical study of pepsinogen C expression in cutaneous malignant melanoma: association with clinicopathological parameters. Int J Biol Markers. 2001;16(4):240–4.PubMedCrossRef
13.
go back to reference Szecsi PB, Dalgaard D, Stakemann G, et al. The concentration of pepsinogen C in human semen and the physiological activation of zymogen in the vagina. Biol Reprod. 1989;40(3):653–9.PubMedCrossRef Szecsi PB, Dalgaard D, Stakemann G, et al. The concentration of pepsinogen C in human semen and the physiological activation of zymogen in the vagina. Biol Reprod. 1989;40(3):653–9.PubMedCrossRef
14.
go back to reference Saito T. Studies on pepsinogen production in advanced gastric cancer tissue. Nihon Geka Gakkai Zasshi. 1989;90(8):1205–12.PubMed Saito T. Studies on pepsinogen production in advanced gastric cancer tissue. Nihon Geka Gakkai Zasshi. 1989;90(8):1205–12.PubMed
15.
go back to reference Chen H, Zhu HR, Yu XN, et al. Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study. Cancer Manag Res. 2019;11:2927–34.PubMedPubMedCentralCrossRef Chen H, Zhu HR, Yu XN, et al. Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study. Cancer Manag Res. 2019;11:2927–34.PubMedPubMedCentralCrossRef
16.
go back to reference Díaz M, Rodríguez JC, Sánchez J, et al. Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma. Int J Biol Markers. 2002;17(2):125–9.PubMedCrossRef Díaz M, Rodríguez JC, Sánchez J, et al. Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma. Int J Biol Markers. 2002;17(2):125–9.PubMedCrossRef
17.
go back to reference Truan N, Vizoso F, Fresno MF, et al. Expression and clinical significance of pepsinogen C in resectable pancreatic cancer. Int J Biol Markers. 2001;16(1):31–6.PubMedCrossRef Truan N, Vizoso F, Fresno MF, et al. Expression and clinical significance of pepsinogen C in resectable pancreatic cancer. Int J Biol Markers. 2001;16(1):31–6.PubMedCrossRef
18.
go back to reference Fernández R, Vizoso F, Rodríguez JC, et al. Expression and prognostic significance of pepsinogen C in gastric carcinoma. Ann Surg Oncol. 2000;7(7):508–14.PubMedCrossRef Fernández R, Vizoso F, Rodríguez JC, et al. Expression and prognostic significance of pepsinogen C in gastric carcinoma. Ann Surg Oncol. 2000;7(7):508–14.PubMedCrossRef
19.
go back to reference Vizoso F, Sánchez LM, Díez-Itza I, et al. Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol. 1995;13(1):54–61.PubMedCrossRef Vizoso F, Sánchez LM, Díez-Itza I, et al. Pepsinogen C is a new prognostic marker in primary breast cancer. J Clin Oncol. 1995;13(1):54–61.PubMedCrossRef
20.
go back to reference Zamyatnin AA Jr, Gregory LC, Townsend PA, et al. Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy. Expert Opin Ther Targets. 2022;26(11):963–77.PubMedCrossRef Zamyatnin AA Jr, Gregory LC, Townsend PA, et al. Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy. Expert Opin Ther Targets. 2022;26(11):963–77.PubMedCrossRef
21.
go back to reference Okumura N, Takao T. The zinc form of carnosine dipeptidase 2 (CN2) has dipeptidase activity but its substrate specificity is different from that of the manganese form. Biochem Biophys Res Commun. 2017;494(3–4):484–90.PubMedCrossRef Okumura N, Takao T. The zinc form of carnosine dipeptidase 2 (CN2) has dipeptidase activity but its substrate specificity is different from that of the manganese form. Biochem Biophys Res Commun. 2017;494(3–4):484–90.PubMedCrossRef
22.
go back to reference Li J, Liu T, Song Y, et al. Discovery of small-molecule degraders of the CDK9-Cyclin T1 complex for targeting transcriptional addiction in prostate cancer. J Med Chem. 2022;65(16):11034–57.PubMedCrossRef Li J, Liu T, Song Y, et al. Discovery of small-molecule degraders of the CDK9-Cyclin T1 complex for targeting transcriptional addiction in prostate cancer. J Med Chem. 2022;65(16):11034–57.PubMedCrossRef
23.
go back to reference Furihata C, Sasajima K, Kazama S, et al. Changes in pepsinogen isozymes in stomach carcinogenesis induced in rats by N-methyl-N’-nitro-N- nitrosoguanidine. J Natl Cancer Inst. 1975;55(4):925–30.PubMedCrossRef Furihata C, Sasajima K, Kazama S, et al. Changes in pepsinogen isozymes in stomach carcinogenesis induced in rats by N-methyl-N’-nitro-N- nitrosoguanidine. J Natl Cancer Inst. 1975;55(4):925–30.PubMedCrossRef
24.
go back to reference Glebov AV, Kalinovskiĭ VP, Seĭts IF. Changes in the content of pepsinogen messenger RNA in the gastric mucosa of rats during N-methyl-N’-nitro-N-nitrosoguanidine-induced carcinogenesis. Eksp Onkol. 1986;8(6):16–8.PubMed Glebov AV, Kalinovskiĭ VP, Seĭts IF. Changes in the content of pepsinogen messenger RNA in the gastric mucosa of rats during N-methyl-N’-nitro-N-nitrosoguanidine-induced carcinogenesis. Eksp Onkol. 1986;8(6):16–8.PubMed
25.
go back to reference Defize J, Derodra JK, Riddell RH, et al. Changes in rat and human pepsinogen phenotypes induced by N’-methyl-N’nitro-N- nitrosoguanidine. Cancer. 1988;62(9):1958–61.PubMedCrossRef Defize J, Derodra JK, Riddell RH, et al. Changes in rat and human pepsinogen phenotypes induced by N’-methyl-N’nitro-N- nitrosoguanidine. Cancer. 1988;62(9):1958–61.PubMedCrossRef
26.
go back to reference Tatematsu M, Aoki T, Inoue T, et al. Coefficient induction of pepsinogen 1-decreased pyloric glands and gastric cancers in five different strains of rats treated with N-methyl-N’-nitro-N-nitrosoguanidine. Carcinogenesis. 1988;9(3):495–8.PubMedCrossRef Tatematsu M, Aoki T, Inoue T, et al. Coefficient induction of pepsinogen 1-decreased pyloric glands and gastric cancers in five different strains of rats treated with N-methyl-N’-nitro-N-nitrosoguanidine. Carcinogenesis. 1988;9(3):495–8.PubMedCrossRef
27.
go back to reference Miyazawa M, Matsuda M, Yano M, et al. Gastric adenocarcinoma of the fundic gland (chief cell-predominant type): A review of endoscopic and clinicopathological features. World J Gastroenterol. 2016;22(48):10523–31.PubMedPubMedCentralCrossRef Miyazawa M, Matsuda M, Yano M, et al. Gastric adenocarcinoma of the fundic gland (chief cell-predominant type): A review of endoscopic and clinicopathological features. World J Gastroenterol. 2016;22(48):10523–31.PubMedPubMedCentralCrossRef
28.
go back to reference Chiba T, Kato K, Masuda T, et al. Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings. Dig Endosc. 2016;28(7):722–30.PubMedCrossRef Chiba T, Kato K, Masuda T, et al. Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings. Dig Endosc. 2016;28(7):722–30.PubMedCrossRef
29.
go back to reference Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34(5):609–19.PubMedCrossRef Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34(5):609–19.PubMedCrossRef
30.
go back to reference Murakami T, Mitomi H, Yao T, et al. Epigenetic regulation of Wnt/β-catenin signal-associated genes in gastric neoplasia of the fundic gland (chief cell-predominant) type. Pathol Int. 2017;67(3):147–55.PubMedCrossRef Murakami T, Mitomi H, Yao T, et al. Epigenetic regulation of Wnt/β-catenin signal-associated genes in gastric neoplasia of the fundic gland (chief cell-predominant) type. Pathol Int. 2017;67(3):147–55.PubMedCrossRef
31.
go back to reference Hidaka Y, Mitomi H, Saito T, et al. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type. Hum Pathol. 2013;44(11):2438–48.PubMedCrossRef Hidaka Y, Mitomi H, Saito T, et al. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type. Hum Pathol. 2013;44(11):2438–48.PubMedCrossRef
32.
go back to reference Ogasawara N, Tsukamoto T, Mizoshita T, et al. RUNX3 expression correlates with chief cell differentiation in human gastric cancers. Histol Histopathol. 2009;24(1):31–40.PubMed Ogasawara N, Tsukamoto T, Mizoshita T, et al. RUNX3 expression correlates with chief cell differentiation in human gastric cancers. Histol Histopathol. 2009;24(1):31–40.PubMed
33.
go back to reference Shimizu T, Sohn Y, Choi E, et al. Decrease in miR-148a expression during Initiation of chief cell transdifferentiation. Cell Mol Gastroenterol Hepatol. 2020;9(1):61–78.PubMedCrossRef Shimizu T, Sohn Y, Choi E, et al. Decrease in miR-148a expression during Initiation of chief cell transdifferentiation. Cell Mol Gastroenterol Hepatol. 2020;9(1):61–78.PubMedCrossRef
34.
go back to reference Meyer AR, Engevik AC, Willet SG, et al. Cystine/glutamate antiporter (xCT) is required for chief cell plasticity after gastric injury. Cell Mol Gastroenterol Hepatol. 2019;8(3):379–405.PubMedPubMedCentralCrossRef Meyer AR, Engevik AC, Willet SG, et al. Cystine/glutamate antiporter (xCT) is required for chief cell plasticity after gastric injury. Cell Mol Gastroenterol Hepatol. 2019;8(3):379–405.PubMedPubMedCentralCrossRef
35.
go back to reference Annunziato S, Kas SM, Nethe M, et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev. 2016;30(12):1470–80.PubMedPubMedCentralCrossRef Annunziato S, Kas SM, Nethe M, et al. Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes Dev. 2016;30(12):1470–80.PubMedPubMedCentralCrossRef
36.
go back to reference Li G, Robinson GW, Lesche R, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 2002;129(17):4159–70.PubMedCrossRef Li G, Robinson GW, Lesche R, et al. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development. 2002;129(17):4159–70.PubMedCrossRef
37.
go back to reference Schade B, Rao T, Dourdin N, et al. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem. 2009;284(28):19018–26.PubMedPubMedCentralCrossRef Schade B, Rao T, Dourdin N, et al. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem. 2009;284(28):19018–26.PubMedPubMedCentralCrossRef
38.
go back to reference Dourdin N, Schade B, Lesurf R, et al. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res. 2008;68(7):2122–31.PubMedPubMedCentralCrossRef Dourdin N, Schade B, Lesurf R, et al. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res. 2008;68(7):2122–31.PubMedPubMedCentralCrossRef
39.
go back to reference Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.PubMedCrossRef Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.PubMedCrossRef
40.
go back to reference Figueiredo J, Söderberg O, Simões-Correia J, et al. The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Eur J Hum Genet. 2013;21(3):301–9.PubMedCrossRef Figueiredo J, Söderberg O, Simões-Correia J, et al. The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Eur J Hum Genet. 2013;21(3):301–9.PubMedCrossRef
41.
go back to reference Humar B, Blair V, Charlton A, et al. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res. 2009;69(5):2050–6.PubMedCrossRef Humar B, Blair V, Charlton A, et al. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res. 2009;69(5):2050–6.PubMedCrossRef
42.
43.
go back to reference Gabriel Goidescu I, Caracostea G, Rotar IC, et al. The influence of reproductive factors on breast cancer risk in women with pathogenic mutations. J BUON. 2019;24(3):1067–74.PubMed Gabriel Goidescu I, Caracostea G, Rotar IC, et al. The influence of reproductive factors on breast cancer risk in women with pathogenic mutations. J BUON. 2019;24(3):1067–74.PubMed
Metadata
Title
The relationship between pepsinogen C and gastric carcinogenesis: a transgene and population study
Authors
Ying E.
Qian Yu
Tao Sun
Hang Xue
Xue-rong Zhao
Hua-chuan Zheng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11020-z

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine